Effects of a Protocol Combining a Non-Irritating Shampoo and an Adelmidrol-Based Adsorbent Mousse on Seborrhoea and Other Signs and Symptoms Secondary to Canine Atopic Dermatitis: A Multicenter, Open-Label Uncontrolled Clinical Trial.

The present study aimed at evaluating the effect of a gentle shampoo and a mousse containing Adelmidrol, tapioca starch and a non-prescription antimicrobial complex on seborrhoea and other clinical signs secondary to canine atopic dermatitis (cAD). Forty-six dogs with cAD-associated seborrhoea and/or pruritus > 4 cm on the pruritus visual analogue scale (P-VAS) and/or bacterial/Malassezia overgrowth were enrolled. The mousse was applied twice daily, and dogs were evaluated at days (D)0, 7, 14 and optionally 28, by means of a skin seborrheic index (SSI), P-VAS, cAD lesion index (CADLI), and a semiquantitative cytological score. The mean SSI value improved during the first two weeks (4.1 ± 0.37 to 1.9 ± 0.30; p < 0.0001). The mean P-VAS score (cm) decreased from 6.6 ± 0.19 at D0 to 3.8 ± 0.31 at D14 (p < 0.0001). The mean CADLI score dropped from 13.7 ± 1.24 to 8.5 ± 1.14 at D14 (p < 0.001). The cytological score for bacteria and Malassezia decreased from 3.2 ± 0.10 and 3.2 ± 0.11, respectively, to 1.2 ± 0.19 and 1.2 ± 0.24 (p < 0.0001). All the investigated signs further improved at D28. Altogether, these observations suggest that the tested protocol might be useful in managing cAD-associated signs.

Molecular interactions between a diphenyl scaffold and PED/PEA15: Implications for type II diabetes therapeutics targeting PED/PEA15 - Phospholipase D1 interaction.

In a recent study, we have identified BPH03 as a promising scaffold for the development of compounds aimed at modulating the interaction between PED/PEA15 (Phosphoprotein Enriched in Diabetes/Phosphoprotein Enriched in Astrocytes 15) and PLD1 (phospholipase D1), with potential applications in type II diabetes therapy. PED/PEA15 is known to be overexpressed in certain forms of diabetes, where it binds to PLD1, thereby reducing insulin-stimulated glucose transport. The inhibition of this interaction reestablishes basal glucose transport, indicating PED as a potential target of ligands capable to recover glucose tolerance and insulin sensitivity. In this study, we employ computational methods to provide a detailed description of BPH03 interaction with PED, evidencing the presence of a hidden druggable pocket within its PLD1 binding surface. We also elucidate the conformational changes that occur during PED interaction with BPH03. Moreover, we report new NMR data supporting the in-silico findings and indicating that BPH03 disrupts the PED/PLD1 interface displacing PLD1 from its interaction with PED. Our study represents a significant advancement toward the development of potential therapeutics for the treatment of type II diabetes.

Psychometric Testing and Validation of the Italian Version of the Helsinki Chronic Pain Index (I-HCPI) in Dogs with Pain Related to Osteoarthritis.

Pain assessment is of paramount importance for properly managing dogs with osteoarthritis (OA) pain. The aim of the present study was to develop and psychometrically validate the Italian version of the Helsinki Chronic Pain Index (I-HCPI). Owners of OA painful (n = 87) and healthy dogs (n = 40) were administered the I-HCPI once or twice after an eight-week meloxicam treatment. Sixty-nine owners of healthy and OA dogs also completed the Italian version of the Canine Brief Pain Inventory (I-CBPI). Pain on palpation on a 0-4 scale was assessed on all recruited dogs. Construct validity was tested both with hypothesis testing and principal component analysis, confirming the I-HCPI accurately measured chronic pain. Good convergent and criterion validity were shown through correlations with I-CBPI subscores and distribution among pain on palpation scores (p < 0.0001). The significant difference between the pre- and post-treatment I-HCPI scores (p < 0.0001) and Cohen's effect size (2.27) indicated excellent responsiveness. The I-HCPI was shown to be reliable through communalities (range 0.47-0.90) and Cronbach α (≥0.95). Discriminative ability and cut-off point, as tested through Receiver Operating Characteristic analysis, showed excellent diagnostic accuracy with a threshold value of 11 (specificity 0.98 and sensitivity 0.94). The I-HCPI was confirmed to be a valid, sensitive, reliable, and accurate tool to discriminate between dogs with and without pain.

Sobre la adherencia al tratamiento: Análisis de un caso clínico a la luz del modelo transteórico / PATIENT'S ADHESION TO TREATMENT: ANALYSIS OF A CLINICAL CASE REFERRED TO A TRANSTHEORETICAL MODEL

Antecedentes: Determinadas patologías crónicas, asociadas con hábitos perniciosos y con las que convive el enfermo durante muchos años afectando cada vez más su calidad de vida y eventualmente amenazando su vida misma, requieren abordajes terapéuticos interdisciplinarios que modifiquen la resistencia a su corrección. Objetivo: demostrar la utilidad del modelo transteórico. Diseño: observacional-descriptivo de un caso clìnico. Lugar de aplicación: Hospital Universitario de atención terciaria. Método: consta de cinco etapas: Precontemplación, Contemplación, Preparación para la acción, Acción y Mantenimiento del cambio logrado (Método Transteórico de Prochaska y Di Clemente). Resultado: Se logró la adhesión del paciente a conductas e indicaciones rechazadas en un principio. Logrando mejorar su control metabólico, y de otros factores de riesgo. Conclusiones:el modelo terapéutico aplicado a este paciente con una enfermedad de evolución crónica sin conciencia de la misma, resultó eficaz

Background: Certain chronic diseases associated with harmful habits with which some patients live for many years that affect both their quality of life and eventually threaten life itself, require multidisciplinary therapeutic approaches that change the patient´s resistance to habits being corrected. Objective: To show the benefits of the transtheoretical model. Design: Observation of case report Setting: tertiary care at University Hospital Method: The method consists of five stages: Precontemplation, Contemplation, Preparation for action, Action, and Maintenance of the achieved change (The Transtheoretical Model by Prochaska & Di Clemente) Result: The patient´s adhesion to behaviour and medical advice which had initially been rejected was achieved. The insulin dose was reduced obtaining adequate glycaemic control, there was an improvement in the lipid profile, and adhesion to the nutritional treatment strengthened. This led to the beginning of body weight loss and the treatment of an ulcer on the sole of the patient´s foot. Conclusions: The therapeutic model applied to this patient with a chronic disease without awareness was effective